Yearly Archives: 2026

Key Highlights Early First-in-Human clinical results have drawn the attention of industry leaders and several of the largest vision care technology companies in the world. Ocumetics will leverage the conference to further engage with global strategic partners to accelerate development and commercialization efforts. Calgary, Canada – TheNewswire - April 1, 2026 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSV:V OTC) (OTCQB: OTCFF) (FRA:

Key Highlights Breakthrough Accommodating Interocular Lens Design: The enhanced lens design introduces several novel concepts that are expected to improve substantially upon the consistency, durability, and manufacturability of the lens. Enhanced Performance with Greater Reliability: This next-generation technology is anticipated to deliver natural optical responsiveness and improved mechanical stability, supporting excellent vision across its full

Calgary, Alberta – February 10, 2026 – TheNewswire - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is pleased to announce that the Corporation has entered into a forbearance agreement with the holders of secured convertible debentures (the “Debentures”) that were issued by the Corporation in May and June 2024 (see press release

Key Highlights   Positive First-in-Human Results: Three-month Group 1 data met or exceeded expectations for safety, lens delivery, and vision performance.   Major De-Risking Milestone: The study successfully validated the core technology and cleared the path to the next clinical phase. Life-Changing Vision Improvements: Patients with severe vision loss experienced meaningful improvements in everyday

Calgary, AB – TheNewswire - January 2, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) is pleased to announce that it has closed the first tranche of its previously announced best efforts brokered private placement of units of the Company (the “Units”) for aggregate gross proceeds of approximately